| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Section of Immunology, McElwain Laboratories, Institute of Cancer Research, Cotswold Road, Belmont, Sutton, Surrey SM2 5NG [S. A. E., G. M. B., W. J. C.], and British Biotech Pharmoaceuticals Ltd. Watlington Rood, Cowley, Oxford OX4 5LY [E. A. B., W. T., P. D. B] United Kingdom
We examined the effects of the synthetic matrix metalloproteinase inhibitor batimastat (BB-94) on lung colonization and spontaneous metastasis of a rat mammary carcinoma, HOSP.1P. This tumor expresses both latent and active forms of the matrix metalloproteinases MMP-2 and MMP-9, although the former, as in human breast cancer, is the most prominent. Administrtion of batimastat (6 ¢ 30 mg/kg i.p.) inhibited by up to 80% both the number and median weights of HOSP.1P lung colonies following i.v. inoculation of cells. This implies an effect both on seeding efficiency and subsequent tumor development. In spontaneous metastasis assays, limited treatment with batimastat (commencing when s.c. tumors were established and continuing until 5 or 14 days after their surgical removal) significantly inhibited lung metastasis but had little effect on lymphatic metastasis. However, when treatment was initiated 2 days prior to surgery and continued until day 70, 100% of animals survived to day 120 when there was no evidence of metastatic disease. All control animals (n = 25) in two separate experiments died before day 100 with lymphatic, lung, and extrapulmonary metastases. Taken together, these data suggest that lymphatic dissemination by HOSP.1P tumor cells is less susceptible to inhibition by botimastat than vascular invasion, but that long-term treatment can effectively prevent the outgrowth of putative micrometastases in both lymph nodes and lungs, allowing sustained tumor-free survival.
1 This work was supported by British Biotech Pharmaceuticals.
2 To whom requests for reprints should be addresed. Phone: (0044) 181 643 8901 ext 4210; Fax: (0044) 181 643 0223; E-mail: suzan@icr.ac.uk.
Received 12/18/95. Accepted 4/16/96.
This article has been cited by other articles:
|
|
 |
|
  T. J. Kaitu'u, J. Shen, J. Zhang, N. B. Morison, and L. A. Salamonsen Matrix Metalloproteinases in Endometrial Breakdown and Repair: Functional Significance in a Mouse Model Biol Reprod, October 1, 2005; 73(4): 672 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ruokolainen, P. Paakko, and T. Turpeenniemi-Hujanen Tissue Inhibitor of Matrix Metalloproteinase-1 Is Prognostic in Head and Neck Squamous Cell Carcinoma: Comparison of the Circulating and Tissue Immunoreactive Protein Clin. Cancer Res., May 1, 2005; 11(9): 3257 - 3264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dona, I. Dell'Aica, E. Pezzato, L. Sartor, F. Calabrese, M. D. Barbera, A. Donella-Deana, G. Appendino, A. Borsarini, R. Caniato, et al. Hyperforin Inhibits Cancer Invasion and Metastasis Cancer Res., September 1, 2004; 64(17): 6225 - 6232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Levesque, F. Liu, P. J. Simmons, T. Betsuyaku, R. M. Senior, C. Pham, and D. C. Link Characterization of hematopoietic progenitor mobilization in protease-deficient mice Blood, July 1, 2004; 104(1): 65 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Sounni, C. Roghi, V. Chabottaux, M. Janssen, C. Munaut, E. Maquoi, B. G. Galvez, C. Gilles, F. Frankenne, G. Murphy, et al. Up-regulation of Vascular Endothelial Growth Factor-A by Active Membrane-type 1 Matrix Metalloproteinase through Activation of Src-Tyrosine Kinases J. Biol. Chem., April 2, 2004; 279(14): 13564 - 13574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Miller, T. J. Saphner, D. M. Waterhouse, T.-T. Chen, A. Rush-Taylor, J. A. Sparano, A. C. Wolff, M. A. Cobleigh, S. Galbraith, and G. W. Sledge A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer Clin. Cancer Res., March 15, 2004; 10(6): 1971 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Chantrain, H. Shimada, S. Jodele, S. Groshen, W. Ye, D. R. Shalinsky, Z. Werb, L. M. Coussens, and Y. A. DeClerck Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment Cancer Res., March 1, 2004; 64(5): 1675 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Trexler, K. Briknarova, M. Gehrmann, M. Llinas, and L. Patthy Peptide Ligands for the Fibronectin Type II Modules of Matrix Metalloproteinase 2 (MMP-2) J. Biol. Chem., March 28, 2003; 278(14): 12241 - 12246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shiraga, S. Yano, A. Yamamoto, H. Ogawa, H. Goto, T. Miki, K. Miki, H. Zhang, and S. Sone Organ Heterogeneity of Host-derived Matrix Metalloproteinase Expression and Its Involvement in Multiple-Organ Metastasis by Lung Cancer Cell Lines Cancer Res., October 15, 2002; 62(20): 5967 - 5973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arlt, C. Kopitz, C. Pennington, K. L. M. Watson, H.-W. Krell, W. Bode, B. Gansbacher, R. Khokha, D. R. Edwards, and A. Kruger Increase in Gelatinase-specificity of Matrix Metalloproteinase Inhibitors Correlates with Antimetastatic Efficacy in a T-Cell Lymphoma Model Cancer Res., October 1, 2002; 62(19): 5543 - 5550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Sweeney, H. Lortat-Jacob, G. V. Priestley, B. Nakamoto, and T. Papayannopoulou Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells Blood, January 1, 2002; 99(1): 44 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Naglich, M. Jure-Kunkel, E. Gupta, J. Fargnoli, A. J. Henderson, A. C. Lewin, R. Talbott, A. Baxter, J. Bird, R. Savopoulos, et al. Inhibition of Angiogenesis and Metastasis in Two Murine Models by the Matrix Metalloproteinase Inhibitor, BMS-275291 Cancer Res., December 1, 2001; 61(23): 8480 - 8485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hoekstra, F.A.L.M. Eskens, and J. Verweij Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives Oncologist, October 1, 2001; 6(5): 415 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Wood and M. C. Archer Matrix Metalloproteinases-2 and 9 Do Not Play a Role in the Growth of Preneoplastic Liver Lesions in F344 Rats Experimental Biology and Medicine, September 1, 2001; 226(8): 799 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Faveeuw, G. Preece, and A. Ager Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases Blood, August 1, 2001; 98(3): 688 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Johnston, J. B.M. Mullen, M. E. Pagura, and R. B. Howard Validation of an orthotopic model of human lung cancer with regional and systemic metastases Ann. Thorac. Surg., April 1, 2001; 71(4): 1120 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sun and M. E. Hemler Regulation of MMP-1 and MMP-2 Production through CD147/Extracellular Matrix Metalloproteinase Inducer Interactions Cancer Res., March 1, 2001; 61(5): 2276 - 2281. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Hidalgo and S. G. Eckhardt Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy J Natl Cancer Inst, February 7, 2001; 93(3): 178 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Krüger, R. Soeltl, I. Sopov, C. Kopitz, M. Arlt, V. Magdolen, N. Harbeck, B. Gänsbacher, and M. Schmitt Hydroxamate-Type Matrix Metalloproteinase Inhibitor Batimastat Promotes Liver Metastasis Cancer Res., February 1, 2001; 61(4): 1272 - 1275. [Abstract] [Full Text]
|
|
|
|
 |
|
 P.-P. H. Lee, J.-J. Hwang, G. Murphy, and M. M. Ip Functional Significance of MMP-9 in Tumor Necrosis Factor-Induced Proliferation and Branching Morphogenesis of Mammary Epithelial Cells Endocrinology, October 1, 2000; 141(10): 3764 - 3773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian Matrix Metalloproteinases: Biologic Activity and Clinical Implications J. Clin. Oncol., March 1, 2000; 18(5): 1135 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Guo, R. Li, S. Zucker, and B. P. Toole EMMPRIN (CD147), an Inducer of Matrix Metalloproteinase Synthesis, Also Binds Interstitial Collagenase to the Tumor Cell Surface Cancer Res., February 1, 2000; 60(4): 888 - 891. [Abstract] [Full Text]
|
|
|
|
|
|
E. K. Rowinsky, R. Humphrey, L. A. Hammond, C. Aylesworth, L. Smetzer, M. Hidalgo, M. Morrow, L. Smith, A. Garner, J. M. Sorensen, et al. Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies J. Clin. Oncol., January 5, 2000; 18(1): 178 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, V. Poulaki, A. Leone, and M. Tsokos Fas-Mediated Apoptosis in Ewing's Sarcoma Cell Lines by Metalloproteinase Inhibitors J Natl Cancer Inst, October 6, 1999; 91(19): 1678 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Aparicio, S. Kermorgant, V. Dessirier, M. J.M. Lewin, and T. Lehy Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats Carcinogenesis, August 1, 1999; 20(8): 1445 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Price, Q. Shi, D. Morris, M. E. Wilcox, P. M. A. Brasher, N. B. Rewcastle, D. Shalinsky, H. Zou, K. Appelt, R. N. Johnston, et al. Marked Inhibition of Tumor Growth in a Malignant Glioma Tumor Model by a Novel Synthetic Matrix MetalloproteinaseInhibitor AG3340 Clin. Cancer Res., April 1, 1999; 5(4): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Macaulay, K. J. O'Byrne, M. P. Saunders, J. P. Braybrooke, L. Long, F. Gleeson, C. S. Mason, A. L. Harris, P. Brown, and D. C. Talbot Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions Clin. Cancer Res., March 1, 1999; 5(3): 513 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Thomas, M. L. Coker, J. L. Zellner, J. R. Handy, A. J. Crumbley III, and F. G. Spinale Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy Circulation, May 5, 1998; 97(17): 1708 - 1715. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
